⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668 | 0.68 | — | — | |
| Bromide SCHEMBL29180858 | 0.63 | — | — | |
| Water SCHEMBL664367 | 0.63 | — | — | |
| Water SCHEMBL5384538 | 0.63 | — | — | |
| Ethyne SCHEMBL4188550 | 0.59 | — | — | |
| SCHEMBL22042585 | 0.59 | — | — | |
| SCHEMBL29358815 | 0.56 | — | — | |
| SCHEMBL567835 | 0.56 | — | — | |
| Bromomethane SCHEMBL13032077 | 0.54 | — | — | |
| Bromomethane SCHEMBL6416803 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4543857-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119546577-A | Modulators of G protein-coupled receptor 88 | 阿卡蒂亚药品公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114805311-B | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023250060-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-114805311-A | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3292101-A1 | TRICYCLIC SULFONES AS ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136375-A1 | DEUTERATED TOZADENANT | CONCERT PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| EP-1622455-A2 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | Bioxell S.p.a. (IT) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004098522-A2 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2004-11-18 | — | — | WO | disclosed |